Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity

Retina

Volumn 34, Issue 1, 2014, Pages 48-54

  Major, James C ^a   Wykoff, Charles C ^a   Mariani, Angeline F ^a   Chen, Eric ^a   Croft, Daniel E ^a   Brown, David M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Age related macular degeneration; AMD; Comparison; Exudative disease; Identifying; Neovascular; OCT; Ocular coherence tomography; Spectral domain; Time domain

Indexed keywords

RANIBIZUMAB;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; IMAGE QUALITY; INTERMETHOD COMPARISON; INTRARETINAL CYST; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; TIME DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CYSTS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84891884987     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182965743     Document Type: Article

References (12)

1. Friedman DS, O'Colmain BJ, Muñoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122: 564-572.
2. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science 1991;254:1178-1181.
3. Sayanagi K, Sharma S, Yamamoto T, Kaiser PK. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology 2009;116: 947-955.
4. Ho J, Sull AC, Vuong LN, et al. Assessment of artifacts and reproducibility across spectral- and time-domain optical coherence tomography devices. Ophthalmology 2009;116:1960-1970.
5. Keane PA, Bhatti RA, Brubaker JW, et al. Comparison of clinically relevant findings from high-speed Fourier-domain and conventional time-domain optical coherence tomography. Am J Ophthalmol 2009;148:242-248.
6. Kiernan DF, Mieler WF, Hariprasad SM. Variety, variability and veracity: macular thickness and reproducibility among optical coherence tomography systems. Am J Ophthalmol 2010;150:138-140.e2.
7. Cukras C, Wang YD, Meyerle CB, et al. Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time-vs. spectral-domain devices. Eye (Lond) 2010;24:775-783.
8. Gupta V, Gupta P, Singh R, et al. Spectral-domain Cirrus highdefinition optical coherence tomography is better than timedomain Stratus optical coherence tomography for evaluation of macular pathologic features in uveitis. Am J Ophthalmol 2008;145:1018-1022.
9. Forooghian F, Cukras C, Meyerle CB, et al. Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci 2008;49:4290-4296.
10. Wykoff CC, Brown D, Chen E, et al. The SAVE (Super-dose Anti-VEgf) trial: 2.0mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina. 2013;44:121-126.
11. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 2011;364: 1897-1908.
12. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular agerelated macular degeneration. Year 2 results. Ophthalmology 2012. Epub ahead of print.